Appointment of Senior Therapeutic Advisor

Leading International Clinical trial expert, Dr. Lynne Hughes, appointed as Advisor to the Company.

IXICO plc, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, announces that it has appointed Dr. Lynne Hughes, an international neurology clinical trial research expert, to IXICO as a Senior Therapeutic Advisor to the Company. Dr. Hughes, who brings more than 35 years of experience in the global clinical research field, will use her deep neurology R&D expertise and knowledge of the global neurology landscape to advise and support IXICO's management in the development of the Company's therapeutic strategy. In particular, Dr. Hughes will focus on determining adjacent therapeutic areas into which IXICO can diversify into and expand the deployment of its proprietary neuroimaging CRO and AI data analytics services.

Dr. Hughes most recently held the position of Vice President and Global Head, Medical and Therapeutic Strategy, Neurology at IQVIA. In a 23-year tenure at IQVIA, Dr. Hughes managed and was senior oversight on more than 450 trials including 125 trials relating to Alzheimer's disease (many of which she designed and managed from concept through to Phase III) and more than 75 trials in Parkinson's disease and 65 trials in Multiple Sclerosis.

Dr. Hughes currently sits on multiple neurology therapeutic focused advisory boards, steering executive committees.  She co-chairs one of the three global taskforces of the G20/World Economic Forum Alzheimer's Collaboration (DAVOS-DAC), the taskforce charged with expediting drug development in Alzheimer's disease, is a senior advisor to the Global Alzheimer's Platform foundation (GAP) and is a member of the NIA/NIH taskforce for recruitment into AD trials and the development of the US National Framework. In addition, Dr. Hughes has worked with various research organisations including the Gates Foundation, Alzheimer's Association, Alzheimer's Research UK, ADI and is a member of the G7 and G20 World Dementia Councils.

Dr. Lynne Hughes commented: "Specialist neuroimaging is now a critical, integral and growing requirement of clinical trials in neurological diseases such as Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. With an increasing interest by the global pharmaceutical industry in precision medicine, there is also considerable R&D investment in the development of new imaging biomarkers across a wide range of rare neurological diseases such as Huntington's Disease and Friedrich's Ataxia. As such, it is essential to ensure that the imaging provider selected by the clinical trial sponsor is at the forefront of imaging technology and advanced data analytics. The team at IXICO are world renowned neuroimaging experts with cutting edge AI algorithm development capabilities and so I am delighted to be working with the team in supporting their current and future clients in executing their CNS strategy to the highest standards."

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to welcome Dr. Hughes to IXICO. Our Company's purpose is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurological disorders. The appointment of Dr. Hughes brings significant additional experience and understanding to enable IXICO to further strengthen and scale our capabilities as the trusted neuroimaging partner of choice to the global pharmaceutical industry"

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews


Date: 02/02/2022